Tentative trade idea for the week $INCY 110C 06/18 expiry Price : 1.5 or less Stoploss: -20% Careful with Wide bid-ask spread.. Please don't buy at market price ..put a limit order.. if it doesn't execute no worries Thesis : Whale is currently sitting at loss on this in full position Almost down 50% Chart: DAILY 2x inside compression on daily , wanting to go higher looks like ... WEEKLY $INCY weekly just did a breakout last Friday ...highest weekly closing ever..... 8 months base breakout here (NOV- JUNE) ... weekly closing was 108.53 just above recent high of 108.39 .... look at the margin ... lol 14 cents Let me know your thoughts in comments section , Thank you ! Enjoy your weekend!

$GT breaks downtrend plus flow

$ZETA is a buy here - Breakout retest of 2B reversal.

idea#2 for the week $FCX 72C Price 65 cents/contract or less

$FCX looks good too

SHORT OIL next week if dea is through $USO $XOM $OXY

tried to go inside but it was closed.

As promised , Pinned the trade idea 💡 See if you all can get an entry ..

Cut the noise, focus on goal /target , learn from mistakes, write them down so you will remember next time , see what worked , identify patterns. improve the process . Results will happen one day !! When you expect the least … Following rules/ Process should happen regardless ..

JUST IN: 🇺🇸🇮🇷 US official says Iran will reopen the Strait of Hormuz without charging transit fees, Fox News reports.

$INCY Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia - In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinib - In essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks) - Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modification - First-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ET - INCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment stocktitan.net/news/INCY/inc…

$INCY INCY Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival "Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25%"

$INCY omg...this will fly premarket or what?

IRANIAN OFFICIAL: TWO KEY ISSUES STILL UNRESOLVED IN PROPOSED U.S.-IRAN MOU OFFICIAL: DEAL COULD BE SIGNED QUICKLY IF U.S. POSITION ON OUTSTANDING ISSUES IS ACCEPTABLE IRAN BELIEVES TRUMP WANTS AGREEMENT SIGNED BEFORE G7 SUMMIT

*TRUMP TO HOLD PRESS CONFERENCE AT 3:30PM CEST, JUNE 17

$INCY flow

Small correction : Not highest weekly closing ever but it is since Nov 2025

$KR whale taking a loss on 67C